Oryzon Genomics, S.A. announced updated Phase Ib clinical data for its selective LSD1 inhibitor iadademstat in acute myeloid leukemia ahead of presentations at the 2026 European Hematology Association Congress, highlighting strong response rates in both newly diagnosed and relapsed or refractory patient populations. The updated ALICE-2 and FRIDA trial findings position the epigenetics-focused developer within an increasingly competitive acute myeloid leukemia market where combination compatibility, tolerability, and remission durability are becoming as important as response rates themselves.

The significance of the update extends beyond the headline efficacy numbers because acute myeloid leukemia treatment is increasingly evolving into a combination-driven field. Earlier generations of therapies often competed as standalone agents, but the current landscape rewards drugs capable of integrating into established treatment backbones. Oryzon Genomics, S.A. appears to be positioning iadademstat precisely within that framework by pairing the LSD1 inhibitor with widely used therapies such as azacitidine, venetoclax, and gilteritinib.

Why LSD1 inhibition is gaining importance in combination-focused acute myeloid leukemia development

LSD1 inhibition has attracted growing attention because of its role in regulating myeloid differentiation and leukemia stem cell biology. Researchers following the field believe targeting LSD1 may help leukemic cells regain differentiation pathways while potentially increasing sensitivity to apoptosis-inducing therapies such as venetoclax.

That mechanistic rationale explains why Oryzon Genomics, S.A. is emphasizing combination-based development rather than positioning iadademstat as a standalone therapy. In the ALICE-2 trial, the company combined iadademstat with azacitidine and venetoclax in newly diagnosed acute myeloid leukemia. In the FRIDA study, the agent was paired with gilteritinib in relapsed or refractory FLT3-mutated disease.

The strategy reflects a broader shift across oncology development. Companies increasingly recognize that improving established treatment regimens can sometimes create larger opportunities than attempting to replace existing standards of care entirely. Venetoclax plus azacitidine already represents an important frontline option for older or unfit acute myeloid leukemia patients. If iadademstat can improve remission quality or durability without significantly increasing toxicity, the mechanism could become clinically relevant despite intense market competition.

Industry observers note that epigenetic therapies have historically struggled to translate promising biology into durable clinical success. The acute myeloid leukemia field therefore remains cautious about early enthusiasm surrounding LSD1 inhibition. Still, the emerging combination data suggest the mechanism may be finding a more commercially and clinically viable role.

Why the ALICE-2 triplet combination data could strengthen Oryzon Genomics, S.A.’s frontline acute myeloid leukemia expansion strategy

The most closely watched dataset comes from the ALICE-2 study evaluating iadademstat alongside azacitidine and venetoclax in newly diagnosed acute myeloid leukemia. Among evaluable patients, the combination produced a reported 100% overall response rate with a composite complete remission rate of 93% and a complete remission rate of 79%.

Those results stand out because frontline acute myeloid leukemia has become one of the most competitive areas in hematologic oncology. Venetoclax-based regimens transformed treatment expectations for patients who previously had limited therapeutic options. The next development phase now centers on identifying which additional agents can further improve remission durability, measurable residual disease clearance, and long-term survival.

The estimated 12-month overall survival rate of 74% may become especially important if future updates continue supporting durability. Acute myeloid leukemia programs frequently produce impressive early response rates that weaken as follow-up matures. Regulators and clinicians are therefore likely to focus heavily on whether remissions remain durable over time.

The tolerability profile may ultimately prove equally important. Venetoclax-containing regimens already require careful management because of cytopenias, infection risk, and dose interruptions. Adding another active therapy can improve efficacy while also increasing operational complexity in routine clinical practice. If iadademstat maintains a manageable safety profile as enrollment expands, the combination could become more commercially attractive.

Another strategic advantage is the apparent flexibility of the mechanism. LSD1 inhibition could theoretically integrate into multiple acute myeloid leukemia combinations beyond venetoclax-based regimens. That possibility raises the prospect that iadademstat may eventually function less as a niche therapy and more as a modular combination component adaptable across different disease subsets.

How the FRIDA study could expand iadademstat’s relevance in molecularly defined disease

The FRIDA trial may prove strategically important because relapsed or refractory FLT3-mutated acute myeloid leukemia remains a difficult treatment setting despite existing targeted therapies. Gilteritinib already serves as a recognized treatment option, but resistance and relapse continue limiting long-term outcomes.

The reported 67% composite complete remission rate in a heavily pre-treated patient population therefore becomes noteworthy, even within a relatively small cohort. Salvage acute myeloid leukemia settings are notoriously difficult because patients often enter treatment with resistant disease biology and cumulative toxicity exposure.

By combining iadademstat with gilteritinib, Oryzon Genomics, S.A. is effectively testing whether epigenetic modulation can improve outcomes within genetically defined disease subsets. That approach aligns with broader oncology trends in which developers increasingly combine targeted therapies with biologically complementary agents rather than relying solely on sequential monotherapy use.

The challenge is that the relapsed or refractory acute myeloid leukemia market is becoming increasingly crowded. Multiple companies are advancing FLT3 inhibitors, menin inhibitors, antibody-drug conjugates, and immune-based therapies across overlapping patient populations. Differentiation will therefore require more than encouraging early response rates.

Clinicians tracking the field will likely watch carefully for measurable residual disease trends, duration of response data, and evidence that the addition of iadademstat alters resistance dynamics. Without those differentiators, even promising remission data may struggle to establish durable positioning.

Why remission durability, treatment scalability, and regulatory scrutiny could determine iadademstat’s long-term acute myeloid leukemia potential

The biggest unanswered question surrounding iadademstat is whether the current data represent the beginning of a scalable therapeutic platform or simply encouraging early-stage signals that become harder to sustain in larger studies. Regulatory scrutiny will likely intensify as patient numbers expand. Early-phase acute myeloid leukemia studies often benefit from small cohorts and shorter exposure periods. Larger studies typically reveal greater efficacy variability and more nuanced toxicity patterns. Maintaining strong remission quality while expanding enrollment will therefore become critical.

Commercial dynamics could also become complicated. Combination oncology regimens are increasingly expensive, and reimbursement pressure continues rising globally. Adding another branded therapy to venetoclax or FLT3-targeted regimens may require exceptionally compelling survival data to justify broader payer adoption.

The updated EHA 2026 data nevertheless strengthen the idea that LSD1 inhibition may be evolving from an experimental concept into a potentially important combination-enabling strategy. Whether iadademstat ultimately becomes a true platform therapy will depend on future survival durability, regulatory alignment, and real-world tolerability as development progresses into larger and more mature clinical settings.

Why iadademstat’s updated AML data could influence the broader future of epigenetic combination oncology

The updated EHA 2026 findings may ultimately matter beyond Oryzon Genomics, S.A. because they contribute to a broader industry reassessment of how epigenetic therapies could fit into next-generation hematologic oncology treatment design. Epigenetic drug development has historically produced uneven commercial outcomes despite compelling biological rationale, partly because many programs struggled to demonstrate durable differentiation against rapidly evolving standards of care.

The emerging iadademstat data suggest LSD1 inhibition may be finding a more viable strategic role as a combination-enabling mechanism rather than a standalone therapeutic category. That distinction could become increasingly important as acute myeloid leukemia development shifts toward multi-agent regimens tailored around disease biology, resistance pathways, and measurable residual disease control.

If larger studies continue showing durable responses with manageable toxicity, industry observers believe LSD1 inhibition could attract broader interest across hematologic malignancies beyond acute myeloid leukemia. The long-term opportunity may therefore depend not only on whether iadademstat succeeds clinically, but also on whether epigenetic modulation becomes a durable pillar of combination oncology strategy in the same way targeted inhibition and immunotherapy platforms previously evolved into backbone treatment technologies.

  acute myeloid leukemia, ALICE-2 trial, AML, azacitidine, FRIDA trial, gilteritinib, hematology, iadademstat, LSD1 inhibitor, Oryzon Genomics, S.A., venetoclax